Experimental Research Of Effect And Mechanism Of Bevacizumab In Pituitary Adenoma

Objective: Drug treatment for pituitary adenoma is rare, only dopamine agonists and somatostatin analognus are useful to prolactin pituitary adenomas and growth hormone of pituitary adenoma, the other types of pituitary adenomas could only rely on the operation. All kinds of pituitary adenomas can secreat VEGF, bevacizumab is a humanized monoclonal antibody against VEGF, but the research of the role of bevacizumab in pituitary adenomas is still rare.Methods: The pituitary adenoma cell line At T20 was treated with bevacizumab, VEGF sectetion into the medium of At T20 was assessed with an ELISA kit. The proliferation of At T20 cell was examined by MTT assay, and the cell apoptosis was measured by flow cytometry. The medium is used to culture the b END.3, a cell line of mouse brain microvascular endothelial cell. VEGFR2 expression was checked with CLSM(Confocal laser scanning microscope) and Westernblot.Results: At T20 cell line could secreat VEGF. Bevacizumab could inhibit At T20 cell proliferation and promote its apoptosis. Thus, through inhibited VEGF, blocked the VEGF/VEGFR2 pathway, bevacizumab ptevented angiogenesis.Conclusion: Bevacizumab showed a clear impact on cell proliferation, cell apoptosis, and involved in VEGF/VEGFR2 pathway. These prompted that bevacizumab might be a new method of anti-angiogenesis for the treatment of pituitary adenoma.